Freeline Therapeutics (FRLN)
NASDAQ: FRLN
· Real-Time Price · USD
6.49
0.01 (0.15%)
At close: Feb 16, 2024, 9:37 PM
Freeline Therapeutics Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | 622K | 617K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | 1.46M | 1.48M | 1.04M | 719.9K | 402.54K | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit | -836.41K | -860.2K | -1.04M | -719.9K | -402.54K | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Income | -67.88M | -79.12M | -90.36M | -98.45M | -112.9M | -124.69M | -136.61M | -142.38M | -140.31M | -134.09M | -115.2M |
Interest Income | 611K | 809K | 1.03M | 904K | 631K | 420K | 294K | 350K | 481K | 396K | 271K |
Pretax Income | -49.45M | -52.25M | -60.56M | -88.6M | -100.26M | -116.28M | -131.82M | -140.05M | -143.68M | -137.73M | -114.56M |
Net Income | -49.93M | -52.74M | -61.07M | -88.97M | -100.67M | -116.66M | -132.18M | -140.39M | -143.77M | -137.87M | -114.56M |
Selling & General & Admin | 29.59M | 31.93M | 30.48M | 30.66M | 32.36M | 36.23M | 42.71M | 44.57M | 48.6M | 39.25M | 32.64M |
Research & Development | 38.15M | 47.14M | 57.15M | 66.2M | 78.17M | 86.08M | 91.52M | 95.43M | 91.71M | 94.84M | 82.56M |
Other Expenses | -1.15M | -1.7M | -1.45M | -1.57M | -1.96M | 2.48M | 1.18M | -165K | -9.54M | -13.52M | -11.88M |
Operating Expenses | 66.86M | 77.75M | 86.19M | 95.29M | 108.67M | 120.55M | 132.35M | 137.91M | 134.62M | 124.66M | 103.03M |
Interest Expense | 6.39M | 6.68M | 6.93M | 6.93M | 547K | 336K | 85K | 85K | 85K | 56K | 56K |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 66.86M | 77.75M | 86.19M | 95.29M | 108.67M | 120.55M | 132.35M | 137.91M | 134.62M | 124.66M | 103.03M |
Income Tax Expense | 481K | 490K | 508K | 368K | 409K | 372K | 355K | 342K | 84K | 145K | 7K |
Shares Outstanding (Basic) | 4.36M | 4.34M | 4.34M | 4.33M | 4.33M | 4.3M | 2.84M | 2.38M | 2.38M | 2.38M | 2.38M |
Shares Outstanding (Diluted) | 4.36M | 4.34M | 4.34M | 4.33M | 4.33M | 4.3M | 2.84M | 2.38M | 2.38M | 2.38M | 2.38M |
EPS (Basic) | -11.47 | -12.14 | -14.11 | -23.81 | -33.06 | -42.58 | -53.68 | -58.98 | -60.35 | -58.17 | -48.65 |
EPS (Diluted) | -11.47 | -12.14 | -14.11 | -23.81 | -33.06 | -42.58 | -53.68 | -58.98 | -60.35 | -58.17 | -48.65 |
EBITDA | -84.22M | -95.18M | -102.13M | -91.87M | -106.63M | -118.33M | -129.99M | -135.52M | -132.26M | -122.42M | -101.04M |
EBIT | -52.72M | -67.26M | -91.1M | -81.06M | -100.64M | -117.45M | -93.61M | -65.83M | -69.49M | -67.28M | -67.28M |
Depreciation & Amortization | -12.75M | -12.15M | -11.77M | 6.58M | 3.34M | 2.94M | 2.74M | 2.39M | 2.36M | 2.24M | 1.99M |